Get 40% Off
Is NVDA a 🟢 buy or 🔴 sell?Unlock Now

Genfit (GNFTp)

BATS Europe
Currency in EUR
Disclaimer
2.94
0.00(0.00%)
Closed

GNFTp Comments

GENFIT : ENFIN COMMERCIALISÉE EN 2024, LA BIOTECH GENFIT
what's the reason of fall of Genfit?
i also want to know
dont worry it Will raise soon 😉
it cheap to buy
Trials for NASH will continue after dataset correction
they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
not all value but a drug development. they have so many programs to continue
damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
Whats the status , will it still go down ?
Yes
this baby Is the brother of contravirpharma (HEPA) .. same diseases.
what do you mean?
WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
 ah you mean to buy because it would be oversold
  i mean if 5 i would buy, and sell at 8
 are you a KOL?
DATA is opn in 1Q 2019?
Huge potential (x3-4 by Q1 2019) After results n PBC mid December. just by comparing with competitors market cap with similar pipeline (intercept, Gilead)
DATA is opn in 1Q 2019?
Huge potential (x3-4 by Q1 2019) After results n PBC mid December. just by comparing with competitors market cap with similar pipeline (intercept, Gilead)
yep this is a sleeping giant
cannot understand how everyone is sleeping on this, unbelievable
 i know, but it seems they want to hold all the markets for them, so always delaying the deadlines, the news and the progress.. They don't want to associate with other pharma to have the final product earlier.. and one big thing is that many hedge fund shorted it thats why it goes down, now only private like you and me have it.. . . But yes it has a HUGE potential.
 what do you mean hold all the markets for them? I don't think they are delaying. Their diagnostic product is the only one around and will be used with all the other NASH drugs in combination. I'm interested more in their diagnostic rather than the actual Elafibranor. Long GENFIT
 instead or dealing with other pharma a have a final product done, they want to do all by themself. by doing this they are late and late in every step. Mr. Mouney admit it.. Second this we've seen on continuous shares holding decrease cause people can't hold it anymore while it was always and always going down. from 33 to 17, off course at some point they exited.. Hopefully they will not postpone the result of phase 3 test...
Nice topic here about genfit ahah :)
The main competitor to Intercept is GENFIT, a pure golden nugget with a pluripotent molecule (GFT505) curing NASH and cardio vascular problems ( not like others, follow my eyes ..). . at the END of the 2b Phase,. . with an excellent safety independant report ,. . with a fast track agreement form the FDA .. FOR NASH ( follow again my eyes ). . and for an valuation 1/10 of is first competitor (follow my ..) ... . you can add that the Genfit molecule will be likely the first on the market for the NASH because of his safety report already published.. . the only problem ... it is an european molecule not easy to trade as US ones. . but on NASDAQ only next year .. better to get some before, the share is close to 34 $ ( with a close amount of shares). . code on the grey market GNFTF. . trading code GNFT.PA
repart demain haussier
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.